Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus-Reference-Cited by-同舟云学术

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Published:2016-02-24 Issue:17 Volume:7 Page:23227-23238
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Xiaochun¹,Kambrick Susan¹,Fu Siqing¹,Naing Aung¹,Subbiah Vivek¹,Blumenschein George R.²,Glisson Bonnie S.²,Kies Merrill S.²,Tsimberidou Apostolia M.¹,Wheler Jennifer J.¹,Zinner Ralph G.¹,Hong David S.¹,Kurzrock Razelle³,Piha-Paul Sarina A.¹

Affiliation:

1. Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

2. Department of Thoracic/Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

3. Division of Hematology and Oncology, University of California San Diego, Moores Cancer Center, San Diego, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors;The Oncologist;2023-06-13

2. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

3. Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis;ACS Omega;2022-06-22

4. Shooting at Moving and Hidden Targets—Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas;Cancers;2021-12-10

5. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma;Medicinal Research Reviews;2021-04-29